LIPOSOMES IN PULMONARY APPLICATIONS: PHYSICOCHEMICAL CONSIDERATIONS, PULMONARY DISTRIBUTION AND ANTIOXIDANT DELIVERY

PDF

Authors
  1. Shek, P.N.
  2. Suntres, Z.E.
  3. Brooks, J.I.
Corporate Authors
Defence and Civil Inst of Environmental Medicine, Downsview ONT (CAN);Toronto Univ, Toronto ONT (CAN) Dept of Clinical Biochemistry
Abstract
The applications of liposomes for improved drug delivery to the lung is promising. Liposome-mediated pulmonary drug delivery promotes an increase in drug retention-time in the lung and more importantly, a reduction in extrapulmonary side-effects, invariably resulting in enhanced therapeutic efficacies. The engineering of an effective liposomal drug formulation for inhalation therapy must take into consideration the leakage problem associated with the nebulization process; vesicle stability and release kinetics within the pulmonary milieu; and, the altered pharmacokinetics of the entrapped drug. The delivery of lipsome-entrapped antioxidants via the tracheobronical route has been found to be very useful in increasing the half-times of the administered agents, thus providing a sustained release effect for prolonged drug action. The entrapment in liposomes of alpha-tocopherol, an extremely insoluble but highly effective antioxidant, has been shown to be very effective in ameliorating oxidant-induced injuries in the lung. The use of bifunctional liposomes containg two antioxidants have been determined to provide excellent resistance to an oxidative challenge and appears to hold promise for improved clinical application in antioxidant therapy.
Keywords
Pharmacokinetics;Drug delivery;Inhalation therapy;Nebulization
Report Number
DCIEM-94-P-20 —
Date of publication
25 May 1994
Number of Pages
12
DSTKIM No
95-02684
CANDIS No
152002
Format(s):
Document Image stored on Optical Disk;Hardcopy

Permanent link

Document 1 of 1

Date modified: